BACKGROUND: Previous studies that were based primarily on small numbers of patients suggested that certain circulating proinflammatory cytokines may be associated with lung cancer; however, large independent studies are lacking. METHODS: Associations between serum interleukin 6 (IL-6) and interleukin 8 (IL-8) levels and lung cancer were analyzed among 270 case patients and 296 control subjects participating in the National Cancer Institute-Maryland (NCI-MD) case-control study. Results were validated in 532 case patients and 595 control subjects in a nested case-control study within the prospective Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Association with C-reactive protein (CRP), a systemic inflammation biomarker, was also analyzed. Associations between biomarkers and lung cancer were estimated using logistic regression models adjusted for smoking, stage, histology, age, and sex. The 10-year standardized absolute risks of lung cancer were estimated using a weighted Cox regression model. RESULTS: Serum IL-6 and IL-8 levels in the highest quartile were associated with lung cancer in the NCI-MD study (IL-6, odds ratio [OR] = 3.29, 95% confidence interval [CI] = 1.88 to 5.77; IL-8, OR = 2.06, 95% CI = 1.19 to 3.57) and with lung cancer risk in the PLCO study (IL-6, OR = 1.48, 95% CI = 1.04 to 2.10; IL-8, OR = 1.57, 95% CI = 1.10 to 2.24), compared with the lowest quartile. In the PLCO study, increased IL-6 levels were only associated with lung cancer diagnosed within 2 years of blood collection, whereas increased IL-8 levels were associated with lung cancer diagnosed more than 2 years after blood collection (OR = 1.57, 95% CI = 1.15 to 2.13). The 10-year standardized absolute risks of lung cancer in the PLCO study were highest among current smokers with high IL-8 and CRP levels (absolute risk = 8.01%, 95% CI = 5.77% to 11.05%). CONCLUSIONS: Although increased levels of both serum IL-6 and IL-8 are associated with lung cancer, only IL-8 levels are associated with lung cancer risk several years before diagnosis. Combination of IL-8 and CRP are more robust biomarkers than either marker alone in predicting subsequent lung cancer.
BACKGROUND: Previous studies that were based primarily on small numbers of patients suggested that certain circulating proinflammatory cytokines may be associated with lung cancer; however, large independent studies are lacking. METHODS: Associations between serum interleukin 6 (IL-6) and interleukin 8 (IL-8) levels and lung cancer were analyzed among 270 case patients and 296 control subjects participating in the National Cancer Institute-Maryland (NCI-MD) case-control study. Results were validated in 532 case patients and 595 control subjects in a nested case-control study within the prospective Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Association with C-reactive protein (CRP), a systemic inflammation biomarker, was also analyzed. Associations between biomarkers and lung cancer were estimated using logistic regression models adjusted for smoking, stage, histology, age, and sex. The 10-year standardized absolute risks of lung cancer were estimated using a weighted Cox regression model. RESULTS: Serum IL-6 and IL-8 levels in the highest quartile were associated with lung cancer in the NCI-MD study (IL-6, odds ratio [OR] = 3.29, 95% confidence interval [CI] = 1.88 to 5.77; IL-8, OR = 2.06, 95% CI = 1.19 to 3.57) and with lung cancer risk in the PLCO study (IL-6, OR = 1.48, 95% CI = 1.04 to 2.10; IL-8, OR = 1.57, 95% CI = 1.10 to 2.24), compared with the lowest quartile. In the PLCO study, increased IL-6 levels were only associated with lung cancer diagnosed within 2 years of blood collection, whereas increased IL-8 levels were associated with lung cancer diagnosed more than 2 years after blood collection (OR = 1.57, 95% CI = 1.15 to 2.13). The 10-year standardized absolute risks of lung cancer in the PLCO study were highest among current smokers with high IL-8 and CRP levels (absolute risk = 8.01%, 95% CI = 5.77% to 11.05%). CONCLUSIONS: Although increased levels of both serum IL-6 and IL-8 are associated with lung cancer, only IL-8 levels are associated with lung cancer risk several years before diagnosis. Combination of IL-8 and CRP are more robust biomarkers than either marker alone in predicting subsequent lung cancer.
Authors: H Takizawa; M Tanaka; K Takami; T Ohtoshi; K Ito; M Satoh; Y Okada; F Yamasawa; A Umeda Journal: Am J Physiol Lung Cell Mol Physiol Date: 2000-05 Impact factor: 5.464
Authors: Edmund A Bermudez; Nader Rifai; Julie Buring; JoAnn E Manson; Paul M Ridker Journal: Arterioscler Thromb Vasc Biol Date: 2002-10-01 Impact factor: 8.311
Authors: F M Brichory; D E Misek; A M Yim; M C Krause; T J Giordano; D G Beer; S M Hanash Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205
Authors: P C Prorok; G L Andriole; R S Bresalier; S S Buys; D Chia; E D Crawford; R Fogel; E P Gelmann; F Gilbert; M A Hasson; R B Hayes; C C Johnson; J S Mandel; A Oberman; B O'Brien; M M Oken; S Rafla; D Reding; W Rutt; J L Weissfeld; L Yokochi; J K Gohagan Journal: Control Clin Trials Date: 2000-12
Authors: Yun-Ling Zheng; Christopher A Loffredo; Zhipeng Yu; Raymond T Jones; Mark J Krasna; Anthony J Alberg; Rex Yung; Donna Perlmutter; Lindsey Enewold; Curtis C Harris; Peter G Shields Journal: Carcinogenesis Date: 2003-02 Impact factor: 4.944
Authors: Nrupen A Bhavsar; Jay H Bream; Alan K Meeker; Charles G Drake; Sarah B Peskoe; Djeneba Dabitao; Angelo M De Marzo; William B Isaacs; Elizabeth A Platz Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-08-22 Impact factor: 4.254
Authors: Hirokazu Okayama; Motonobu Saito; Naohide Oue; Jonathan M Weiss; Jimmy Stauffer; Seiichi Takenoshita; Robert H Wiltrout; S Perwez Hussain; Curtis C Harris Journal: Int J Cancer Date: 2012-06-13 Impact factor: 7.396
Authors: Tess V Clendenen; Karen L Koenig; Alan A Arslan; Annekatrin Lukanova; Franco Berrino; Yian Gu; Goran Hallmans; Annika Idahl; Vittorio Krogh; Anna E Lokshin; Eva Lundin; Paola Muti; Adele Marrangoni; Brian M Nolen; Nina Ohlson; Roy E Shore; Sabina Sieri; Anne Zeleniuch-Jacquotte Journal: Cytokine Date: 2011-10-19 Impact factor: 3.861
Authors: Jun Wang; I-Min Lee; Shelley S Tworoger; Julie E Buring; Paul M Ridker; Bernard Rosner; Susan E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-20 Impact factor: 4.254
Authors: Joshua Demb; Esther K Wei; Monika Izano; Stephen Kritchevsky; Helen Swede; Anne B Newman; Michael Shlipak; Tomi Akinyemiju; Steven Gregorich; Dejana Braithwaite Journal: J Geriatr Oncol Date: 2018-08-03 Impact factor: 3.599
Authors: Bríd M Ryan; Ana I Robles; Andrew C McClary; Majda Haznadar; Elise D Bowman; Sharon R Pine; Derek Brown; Mohammed Khan; Kouya Shiraishi; Takashi Kohno; Hirokazu Okayama; Ramakrishna Modali; Jun Yokota; Curtis C Harris Journal: Cancer Res Date: 2014-12-05 Impact factor: 12.701